References
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management and prevention of COPD2017 Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copdAccessed April 7, 2017
- CazzolaMSegretiAMateraMGNew developments in the combination treatment of COPD: focus on umeclidinium/vilanterolDrug Des Devel Ther2013712011208
- BrusascoVReducing cholinergic constriction: the major reversible mechanism in COPDEur Respir Rev200615993236
- MontuschiPCiabattoniGBronchodilating drugs for chronic obstructive pulmonary disease: current status and future trendsJ Med Chem201558104131416425587755
- van NieuwstadtRAHenricksPAHajerRvan der MeerWABreukinkHJNijkampFPCharacterization of muscarinic receptors in equine tracheal smooth muscle in vitroVet Q199719254579225432
- ANORO ELLIPTA™ [summary of product characteristics]2017 Available from: http://www.medicines.org.uk/emc/medicine/28949Accessed April 7, 2017
- ANORO ELLIPTA™ [highlights of prescribing information]2017 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-MG.PDFAccessed April 7, 2017
- INCRUSE ELLIPTA™ [highlights of prescribing information]2016 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Incruse_Ellipta/pdf/INCRUSE-ELLIPTA-PI-PIL.PDFAccessed April 7, 2017
- INCRUSE™ [summary of product characteristics]2017 Available from: https://www.medicines.org.uk/emc/medicine/29394Accessed April 7, 2017
- ANORO ELLIPTA™ [product monograph]2017 Available from: http://ca.gsk.com/media/588409/anoro-ellipta.pdfAccessed April 7, 2017
- INCRUSE ELLIPTA™ [product monograph]2017 Available from: http://ca.gsk.com/media/591190/incruse_ellipta.pdfAccessed April 7, 2017
- DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
- DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
- WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
- JohnsonMMolecular mechanisms of β2-adrenergic receptor function, response, and regulationJ Allergy Clin Immunol20061171182416387578
- WiddopSDaykinKHallIPExpression of muscarinic M2 receptors in cultured human airway smooth muscle cellsAm J Respir Cell Mol Biol1993955415468217196
- CanningBJFischerANeural regulation of airway smooth muscle toneRespir Physiol20011251–211312711240156
- HeximerSPRGS2-mediated regulation of GqαMethods Enzymol2004390658215488171
- HoldenNSBellMJRiderCFβ2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoidsProc Natl Acad Sci U S A201110849197131971822080612
- SalmonMLuttmannMAFoleyJJPharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseasesJ Pharmacol Exp Ther2013345226027023435542
- SlackRJBarrettVJMorrisonVSIn vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of actionJ Pharmacol Exp Ther2013344121823023131596
- MalerbaMRadaeliAMontuschiPMorjariaJBVilanterol trifenatate for the treatment of COPDExpert Rev Respir Med201610771973127143334
- EskinSGSybersHDLesterJWNavarroLTGottoAMJrDeBakeyMEHuman smooth muscle cells cultured from atherosclerotic plaques and uninvolved vessel wallIn Vitro19811787137187327599
- KangHSMoonYJKimYYSmooth-muscle progenitor cells isolated from patients with moyamoya disease: novel experimental cell modelJ Neurosurg2014120241542524160477
- ChengYPrusoffWHRelationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochem Pharmacol19732223309931084202581
- ProcopiouPABarrettVJBevanNJSynthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approachJ Med Chem201053114522453020462258
- ApariciMGavaldàARamosIIn vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterolEur J Pharmacol2016770616926656755
- CapoteLAMendez PerezRLymperopoulosAGPCR signaling and cardiac functionEur J Pharmacol2015763Pt B14314825981298
- LymperopoulosARengoGKochWJAdrenergic nervous system in heart failure: pathophysiology and therapyCirc Res2013113673975323989716
- HananiaNAFeldmanGZachgoWThe efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialChest2012142111912722241764
- ColeridgeHMColeridgeJCSchultzHDAfferent pathways involved in reflex regulation of airway smooth musclePharmacol Ther19894211632657805
- GronebergDAQuarcooDFrossardNFischerANeurogenic mechanisms in bronchial inflammatory diseasesAllergy200459111139115215461593
- JiménezEGámezMIBragadoMJMontielMMuscarinic activation of mitogen-activated protein kinase in rat thyroid epithelial cellsCell Signal200214866567212020766
- ProfitaMAlbanoGDRiccobonoLIncreased levels of Th17 cells are associated with non-neuronal acetylcholine in COPD patientsImmunobiology2014219539240124529390
- PeraTPennRBCrosstalk between β-2-adrenoceptor and muscarinic acetylcholine receptors in the airwayCurr Opin Pharmacol201416728124747364
- ToveySCWillarsGBSingle-cell imaging of intracellular Ca2+ and phospholipase C activity reveals that RGS 2, 3, and 4 differentially regulate signaling via the Gαq/11-linked muscarinic M3 receptorMol Pharmacol20046661453146415383626
- BernsteinLSRamineniSHagueCRGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11α signalingJ Biol Chem200427920212482125614976183
- HeximerSPWatsonNLinderMEBlumerKJHeplerJRRGS2/G0S8 is a selective inhibitor of Gqα functionProc Natl Acad Sci U S A1997942614389143939405622
- ToveySCTaylorCWCyclic AMP directs inositol (1,4,5)-trisphosphate-evoked Ca2+ signalling to different intracellular Ca2+ storesJ Cell Sci2013126Pt 102305231323525004
- MarkMDWittemannSHerlitzeSG protein modulation of recombinant P/Q-type calcium channels by regulators of G protein signalling proteinsJ Physiol2000528Pt 1657711018106
- XieZLiuDLiuSIdentification of a cAMP-response element in the regulator of G-protein signaling-2 (RGS2) promoter as a key Cis-regulatory element for RGS2 transcriptional regulation by angiotensin II in cultured vascular smooth musclesJ Biol Chem201128652446464465822057271
- HoldenNSGeorgeTRiderCFInduction of regulator of G-protein signaling 2 expression by long-acting β2-adrenoceptor agonists and glucocorticoids in human airway epithelial cellsJ Pharmacol Exp Ther20143481122424163441